Literature DB >> 6636983

The use of the 2 substituted 5-nitroimidazole, Fexinidazole (Hoe 239) in the treatment of chronic T. brucei infections in mice.

F W Jennings, G M Urquhart.   

Abstract

Relapse of chronic T. brucei infections was completely prevented by treating with either diminazene aceturate (Berenil) at 40 mg/kg or suramin (Germanin) at 20 mg/kg followed by four doses of the 2-substituted 5-nitroimidazole (Fexinidazole) (Hoe 239). None of these drugs administered singly elicited 100% permanent cures although a high percentage of the mice were cured with four doses of Fexinidazole at 250 mg/kg. A single dose of 20 mg/kg suramin followed by four daily doses of 30 mg/kg Fexinidazole will effectively eliminate all the trypanosomes from the brains of chronically infected mice.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6636983     DOI: 10.1007/BF00926669

Source DB:  PubMed          Journal:  Z Parasitenkd        ISSN: 0044-3255


  8 in total

1.  Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.

Authors:  E J Freireich; E A Gehan; D P Rall; L H Schmidt; H E Skipper
Journal:  Cancer Chemother Rep       Date:  1966-05

2.  The relationship between duration of infection with Trypanosoma brucei in mice and the efficacy of chemotherapy.

Authors:  F W Jennings; D D Whitelaw; G M Urquhart
Journal:  Parasitology       Date:  1977-10       Impact factor: 3.234

3.  Difference of effective antitrypanosomal dosages of benznidazole in mice and man. Chemotherapeutic and pharmacokinetic results.

Authors:  R W Richle; J Raaflaub
Journal:  Acta Trop       Date:  1980-09       Impact factor: 3.112

4.  'Berenil' and nitroimidazole combinations in the treatment of Trypanosoma brucei infection with central nervous system involvement.

Authors:  F W Jennings; G M Urquhart; P K Murray; B M Miller
Journal:  Int J Parasitol       Date:  1980-02       Impact factor: 3.981

5.  Relapsed parasitaemia following chemotherapy of chronic T. brucei infections in mice and its relation to cerebral trypanosomes.

Authors:  F W Jennings; G D Gray
Journal:  Contrib Microbiol Immunol       Date:  1983

6.  The activity of fexinidazole (HOE 239) against experimental infections with Trypanosoma cruzi, trichomonads and Entamoeba histolytica.

Authors:  W Raether; H Seidenath
Journal:  Ann Trop Med Parasitol       Date:  1983-02

7.  The use of Erlangen diamidine 98/202 in relapsing Trypanosoma brucei infections in mice.

Authors:  F W Jennings; G D Gray; G M Urquhart
Journal:  Trans R Soc Trop Med Hyg       Date:  1982       Impact factor: 2.184

8.  Treatment with suramin and 2-substituted 5-nitroimidazoles of chronic murine Trypanosoma brucei infections with central nervous system involvement.

Authors:  F W Jennings; G M Urquhart; P K Murray; B M Miller
Journal:  Trans R Soc Trop Med Hyg       Date:  1983       Impact factor: 2.184

  8 in total
  16 in total

1.  Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.

Authors:  Antoaneta Y Sokolova; Susan Wyllie; Stephen Patterson; Sandra L Oza; Kevin D Read; Alan H Fairlamb
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

2.  Trypanocidal drugs and their effect on parasitaemia, specific IgG production and protective immunity in rats infected with Trypanosoma lewisi.

Authors:  C M Ndarathi
Journal:  Parasitol Res       Date:  1992       Impact factor: 2.289

Review 3.  Innovative Partnerships for the Elimination of Human African Trypanosomiasis and the Development of Fexinidazole.

Authors:  Philippe Neau; Heinz Hänel; Valérie Lameyre; Nathalie Strub-Wourgaft; Luc Kuykens
Journal:  Trop Med Infect Dis       Date:  2020-01-27

4.  A novel microwave synthesis of quinoline-3-carboxylic acid derivatives for treatment against human African trypanosomiasis.

Authors:  Bhupesh S Samant; Nyaradzai Nyangari
Journal:  Mol Divers       Date:  2012-10-10       Impact factor: 2.943

5.  Investigational drugs for visceral leishmaniasis.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  Expert Opin Investig Drugs       Date:  2014-11-20       Impact factor: 6.206

6.  Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness.

Authors:  Marcel Kaiser; Michael A Bray; Monica Cal; Bernadette Bourdin Trunz; Els Torreele; Reto Brun
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

7.  Assessing the trypanocidal potential of natural and semi-synthetic diketopiperazines from two deep water marine-derived fungi.

Authors:  Katharine R Watts; Joseline Ratnam; Kean-Hooi Ang; Karen Tenney; Jennifer E Compton; James McKerrow; Phillip Crews
Journal:  Bioorg Med Chem       Date:  2010-03-01       Impact factor: 3.641

8.  Investigation of thiazolyl-benzothiophenamides as potential agents for African sleeping sickness.

Authors:  Ronald W Brown; Ashraf M Abdel-Megeed; Paul A Keller; Amy J Jones; Melissa L Sykes; Marcel Kaiser; Jonathan B Baell; Vicky M Avery; Christopher J T Hyland
Journal:  RSC Med Chem       Date:  2020-09-23

9.  Assessing the essentiality of Leishmania donovani nitroreductase and its role in nitro drug activation.

Authors:  Susan Wyllie; Stephen Patterson; Alan H Fairlamb
Journal:  Antimicrob Agents Chemother       Date:  2012-12-03       Impact factor: 5.191

10.  The use of 2-substituted 5-nitroimidazoles in the treatment of chronic murine Trypanosoma brucei infections with central nervous system involvement.

Authors:  F W Jennings; G M Urquhart; P K Murray; B M Miller
Journal:  Z Parasitenkd       Date:  1984
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.